EUCTR2004-001107-36-BE进行中（未招募）不适用
A comparison of Symbicort Single inhaler Therapy (Symbicort Turbohaler 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multi-centre study (SALTO) - SALTO
AstraZeneca NV/SA0 个研究点目标入组 1,200 人开始时间: 2005年8月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study patients must fulfil all of the following criteria at Visit 1:
- •1.Provision of written informed consent. This must have been obtained before conducting any study related procedures. For underage patients, informed consent from both patient and the patient’s parent/legal guardian must be obtained. Female or male outpatients aged ³12 years.
- •2.Minimum of 3 months documented history of asthma, diagnosed according to the American Thoracic Society (ATS) definition (Error! Reference source not found.).
- •3.Prescribed inhaled GCS at a dose of ³320 µg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1.
- •- daily maintenance treatment with both inhaled GCS and long-acting b2-agonist (LABA)
- •- daily treatment with inhaled GCS alone (i.e. without LABA) and a history of sub optimal asthma control the month prior to enrolment as judged by the investigator and use of ³3 inhalations of as needed medication for symptom relief during the last 7 days before enrolment.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any of the following is regarded as a criterion for exclusion from the study:
- •1.Previous treatment with Symbicort Single inhaler Therapy (use of Symbicort Turbohaler for both maintenance treatment and as needed in response to symptoms as described in Section Error! Reference source not found.).
- •2.Use of any b-blocking agent, including eye-drops.
- •3.Use of oral GCS as maintenance treatment.
- •4.Known or suspected hypersensitivity to study therapy or excipients.
- •5.A history of smoking ³ 10 pack years (1 pack year = 1 pack (20 cigarettes) per day for one year or equivalent).
- •6.Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator.
- •7.Any significant disease or disorder, which, in the opinion of the investigator, may put the patient at risk because of participating in the study.
- •8.Any non-asthma related, clinically significant abnormal finding in physical examination and/or vital signs at Visit 1, which in the opinion of the investigator, may put the patient at risk because of his/her participation in the study.
- •9.Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to or at visit 1
- •10.Planned in-patient hospitalisation during the course of the study.
- •11.Suspected poor capability to follow instructions of the study, e.g. because of a history of drug abuse, difficulty in reading and/or understand instructions or any other reason, as judged by the investigator.
- •12.Previous allocation of randomisation code in this study.
- •13.Participating in another clinical trial during the course of this study or within 30 days prior to Visit 1.
- •14.Involvement in the planning or conduct of this study.
研究者
相似试验
进行中（未招募）
不适用
A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multicentre study - STYLEThis is a Phase IIIB trial to be conducted in patients with persistent asthmaMedDRA version: 7.0Level: LLTClassification code 10003553EUCTR2005-000532-25-LTAstraZeneca AB1,000
进行中（未招募）
1 期
A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multicentre study - STYLEEUCTR2005-000532-25-SKAstraZeneca AB1,000
进行中（未招募）
1 期
A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multicentre study - STYLEThis is a Phase IIIB trial to be conducted in patients with persistent asthmaMedDRA version: 7.0Level: LLTClassification code 10003553EUCTR2005-000532-25-CZAstraZeneca AB995
进行中（未招募）
不适用
A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multicentre study - STYLEEUCTR2005-000532-25-ISAstraZeneca AB1,000
进行中（未招募）
不适用
A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multicentre study - STYLEEUCTR2005-000532-25-LVAstraZeneca Portugal1,000